Achieve Life Sciences

While the therapy could be the first new U.S. prescription cessation drug in two decades and shows lower nausea than class comparators, pricing will be anchored by payer scrutiny and generics. ICER’s benchmark suggests value‑consistent net pricing around 1,700 to 2,400 dollars per 12‑week course.

That range implies room for attractive gross margins but not unconstrained price action. Latent pricing power could expand with a vaping label where there is no approved therapy, but we handicap this until approval.